Ibutamoren

Overview

MK-677 (Ibutamoren) is a non-peptide ghrelin receptor agonist that stimulates GH release orally. Unlike injectable secretagogues (CJC-1295, Ipamorelin, Sermorelin), MK-677 is taken as a pill and provides sustained GH/IGF-1 elevation for up to 24 hours per dose.

Key Benefits

• Oral Administration: No injections required — oral bioavailability
• 24-Hour GH Elevation: Single daily dose maintains elevated GH pulsatility
• IGF-1 Increase: Raises IGF-1 by 40-97% in clinical studies
• Sleep Quality: Dramatically improves deep sleep (Stage 3/4 NREM)
• Lean Mass: Increases nitrogen retention and lean body mass
• Bone Density: Improved markers of bone turnover

MK-677 vs Injectable Secretagogues

| | MK-677 | CJC/Ipa | Sermorelin | |---|---|---|---| | Route | Oral | Injection | Injection | | Duration | 24 hours | 2-4 hours | 1-2 hours | | GH Pattern | Sustained elevation | Pulsatile | Pulsatile | | Appetite | Significant increase | Minimal | Minimal | | Water Retention | Common | Mild | Minimal | | IGF-1 Increase | Large (40-97%) | Moderate | Modest |

The Appetite Effect

MK-677 activates ghrelin receptors — the hunger hormone. Most users experience significant appetite increase, especially in the first 2-4 weeks. This can be a benefit (for underweight or hard-gainer individuals) or a drawback (for those trying to lose fat). Taking the dose before bed reduces daytime hunger impact.

Clinical Evidence

Multiple clinical trials in elderly, obese, and GH-deficient populations showing:

• Sustained IGF-1 elevation over 12 months
• Improved sleep architecture
• Increased lean mass without exercise intervention
• Improved nitrogen balance

Mechanism of Action

MK-677 is a non-peptide agonist at the ghrelin receptor (GHS-R1a). It mimics ghrelin's GH-releasing effect on pituitary somatotrophs, stimulating sustained GH secretion. Unlike GHRH-based secretagogues, ghrelin receptor activation also increases appetite (via hypothalamic NPY/AgRP neurons) and modulates glucose metabolism.

Research Status

Multiple Phase II clinical trials. Published in JCEM, J Clin Invest, and others. Extensive clinical data but not FDA-approved. Widely available as research compound.

Safety Profile

Common: increased appetite (significant), water retention/bloating, lethargy in first week, vivid dreams. Less common: numbness/tingling in hands (carpal tunnel-like), mild blood sugar elevation. Monitor fasting glucose. Reduce dose if water retention excessive. Taking before bed minimizes appetite/lethargy.

Related Compounds